Inactive

Notice of Intent to Award a Sole Source Contract to the State of Montana, State of Georgia, and the State of North Carolina – FDA-2023-116621 The Food and Drug Administration (FDA) intends to award co... Notice of Intent to Award a Sole Source Contract to the State of Montana, State of Georgia, and the State of North Carolina – FDA-2023-116621 The Food and Drug Administration (FDA) intends to award contracts to the State of Montana, State of Georgia and the State of North Carolina to assist in inspecting retail establishments that sell cigarettes and/or smokeless tobacco products and in surveillance of other entities that fall under the scope of the Tobacco Control Act and the provisions that will be cited in the request for proposal (RFP). All interested parties must be an agency or subdivision of a state, territory, local, or tribal government that has the power to create, enforce, or administer rules or policies that govern the conduct of individuals or other private entities such as small businesses. The proposed contract action is for services for which the Government intends to solicit and negotiate with ONLY state organizations under the authority of 41 U.S.C. 3304(a)(5). This notice is issued for informational purposes and is not a request for competitive proposals. Any interested party should respond with a statement of your intent to submit a proposal in response to the FDA-2023-116621 RFP. Any interested party shall submit a capabilities statement and/or a statement of intent to include a description of your legal authority, organizational capability, and staffing capacity to conduct tobacco compliance check inspections, a point of contact, official agency name, address, and valid Unique Entity ID number. It shall not exceed 5 double spaced pages. The solicitation will be available before mid-April 2023 on the System for Award Management website at www.sam.gov. It is the offerors responsibility to monitor the System for Award Management website for the release of the solicitation and amendments. Responses to this notice must be sent via email to Janice Heard at Janice.Heard@fda.hhs.gov by close of business March 28, 2023